Inclusion Criteria:

- History of histologically documented MM with relapsed or progressive disease after
either scheduled tandem or one autologous transplantation.

- Patient has measurable disease in which to capture response.

- Performance status of 2 as per Zubroid scale, unless PS of 3-4 based solely on bone
pain.

- Patients must have a platelet count 75,000/μL, and an ANC of at least 1,000/μL.

- Patients must have adequate renal function defined as serum creatinine < 2.5 mg/dL.

- Patients must have adequate hepatic function defined as serum transaminases and
direct bilirubin < 2 x the upper limit of normal.

- Pregnant or nursing women may not participate. Women of childbearing potential must
have a negative pregnancy documented within one week of registration. Women of
reproductive potential may not participate unless they have agreed to use an
effective contraceptive method.

- Male or female adults of at least 18 years of age.

- Patients must have signed an IRB-approved written informed consent form and
demonstrate willingness to meet follow-up schedule and study procedure obligations.

Exclusion Criteria:

- Chemotherapy or radiotherapy received within the previous 2 weeks.

- Significant neurotoxicity, defined as grade > 2 neurotoxicity per NCI Common Toxicity
Criteria (See Appendix).

- Platelet count < 75,000/mm3, or ANC < 1,000/μl.

- Clinically significant hepatic dysfunction as noted by bilirubin or AST > 3 times the
upper normal limit or clinically significant concurrent hepatitis.

- New York Hospital Association (NYHA) Class III or Class IV heart failure.

- Myocardial infarction within the last 6 months.

- Uncontrolled, active infection requiring IV antibiotics.

- Patients with a history of treatment for clinically significant ventricular cardiac
arrhythmias.

- Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric
illness that could potentially interfere with the completion of treatment according
to this protocol.

- Pregnant or potential for pregnancy. Women of childbearing potential will have a
pregnancy test at screening, and will be required to use a medically approved
contraceptive method.

- Breast-feeding women may not participate.